"Our near-term prospects are extremely strong. We are positioned to return to robust growth in 2025 and deliver top-tier financial performance through the end of the decade." AbbVie's stock was up less than 1% today, trading at about $147. AbbVie now plans to scale down its acquisition strategy, Chief Operating Officer Robert Michael told investors. While the company will continue to pursue small, early-stage deals, Michael said he doesn't anticipate more megadeals for the "foreseeable future."